Sulfated Dextrans Enhance In Vitro Amplification of Bovine Spongiform Encephalopathy PrPSc and Enable Ultrasensitive Detection of Bovine PrPSc

Yuichi Murayama1*, Miyako Yoshioka1,2, Kentaro Masujin1, Hiroyuki Okada1, Yoshifumi Iwamaru1, Morikazu Imamura1, Yuichi Matsuura1, Shigeo Fukuda3, Sadao Onoe3, Takashi Yokoyama1, Shirou Mohri1

1 Prion Disease Research Center, National Institute of Animal Health, Tsukuba, Japan, 2 Safety Research Team, National Institute of Animal Health, Tsukuba, Japan, 3 Hokkaido Animal Research Center, Shintoku, Japan

Abstract

Background: Prions, infectious agents associated with prion diseases such as Creutzfeldt-Jakob disease in humans, bovine spongiform encephalopathy (BSE) in cattle, and scrapie in sheep and goats, are primarily comprised of PrPSc, a protease-resistant misfolded isoform of the cellular prion protein PrPC. Protein misfolding cyclic amplification (PMCA) is a highly sensitive technique used to detect minute amounts of scrapie PrPSc. However, the current PMCA technique has been unsuccessful in achieving good amplification in cattle. The detailed distribution of PrPSc in BSE-affected cattle therefore remains unknown.

Methodology/Principal Findings: We report here that PrPSc derived from BSE-affected cattle can be amplified ultra-efficiently by PMCA in the presence of sulfated dextran compounds. This method is capable of amplifying very small amounts of PrPSc from the saliva, palatine tonsils, lymph nodes, ileocecal region, and muscular tissues of BSE-affected cattle. Individual differences in the distribution of PrPSc in spleen and cerebrospinal fluid samples were observed in terminal-stage animals. However, the presence of PrPSc in blood was not substantiated in the BSE-affected cattle examined.

Conclusions/Significance: The distribution of PrPSc is not restricted to the nervous system and can spread to peripheral tissues in the terminal disease stage. The finding that PrPSc could be amplified in the saliva of an asymptomatic animal suggests a potential usefulness of this technique for BSE diagnosis. This highly sensitive method also has other practical applications, including safety evaluation or safety assurance of products and byproducts manufactured from bovine source materials.

Citation: Murayama Y, Yoshioka M, Masujin K, Okada H, Iwamaru Y, et al. (2010) Sulfated Dextrans Enhance In Vitro Amplification of Bovine Spongiform Encephalopathy PrPSc and Enable Ultrasensitive Detection of Bovine PrPSc. PLoS ONE 5(10): e13152. doi:10.1371/journal.pone.0013152

Introduction

Prions, the infectious agents associated with transmissible spongiform encephalopathies, are characterized by the accumulation of PrPSc and are believed to have infected cattle due to feeding cattle meat and bone meal (MBM) contaminated with PrPSc acquired from rendering carcasses of BSE- or scrapie-infected ruminants [4,5]. Since variant CJD (vCJD) is suspected to be attributable to infectious agents associated with BSE [6–8], prophylactic hygiene dictates that infected cattle be identified and eradicated.

Immunological methods such as enzyme-linked immunosorbent assays and western blotting (WB) have been widely used for the detection of PrPSc. It is now possible to perform in vivo amplification of hamster scrapie PrPSc using the protein misfolding cyclic amplification (PMCA) technique [9]. Extremely small amounts of PrPSc can be detected by combining PMCA with WB [10,11]. PMCA has been used to amplify PrPSc from mice [12], deer [13], sheep [14], and humans [15]. PMCA has also been applied to the detection of bovine PrPSc in cattle [16], and serial PMCA has been shown to improve detection sensitivity [17]. Although hyperefficient amplification of a mouse-adapted BSE strain has been demonstrated [18], there are no reports that cite ultrasensitive and direct detection of bovine PrPSc in cattle using the current PMCA method.
Since the concentration of PrPSc in tissues or body fluids of BSE-infected animals is expected to be extremely low, the development of a sensitive method for detecting PrPSc in infected cattle is important. In the present study, we developed an extremely efficient method that is suitable for bovine PrPSc amplification. The method, which involves amplifying BSE PrPSc in the presence of sulfated dextran compounds, enables sensitive detection of PrPSc at levels equivalent to those obtained for detection of hamster PrPSc [19]. This method is capable of amplifying very small amounts of PrPSc from the saliva, palatine tonsils, lymph nodes, ileocecal region, and muscular tissues of BSE-affected cattle. The technology will result in a marked improvement in BSE safety.

Results

Sulfated dextran compounds enhanced BSE PrPSc amplification

In general, the efficiency of BSE PrPSc amplification using PMCA was low compared to amplification of hamster and mouse scrapie PrPSc (Figure 1A). We attempted to improve BSE PrPSc amplification efficiency using high temperature conditions (39°C and higher). Various reagents were screened for their ability to prevent thermal denaturation of the brain homogenate, and we found that sulfated dextran compounds were suitable for this purpose. Unexpectedly, the BSE PrPSc amplification efficiency was greatly increased when amplification was performed in the presence of sulfated dextran compounds at 37°C.

The signal intensities of amplified PrPSc upon WB were significantly higher in samples containing sodium dextran sulfate with a high molecular weight of 900–2000 kDa (DSS-H) at a final concentration of 0.25–1% (Figure 1A, right panel). This enhancement was dependent upon the polarity and molecular size of the dextran compound. Smaller anionic sodium dextran sulfate (DSS-L) and potassium dextran sulfate (DSP) were more effective than the high molecular weight compounds, but positively charged DEAE-dextran and dextrans covering a range of molecular weights had little or no effect on amplification (Figure 1B). Glycosaminoglycans that are distributed throughout animal tissues and a sulfated polysaccharide were not effective at the concentrations examined (Figure 1C).

In contrast, in vitro amplification of sheep scrapie PrPSc was completely inhibited by the addition of DSP to the reaction mixture (Figure 2A). A similarly inconsistent experimental result

![Figure 1](image-url)
was obtained with pentosan polysulfate (PPS), which may be effective in treating CJD [20,21]. This reagent acted as an inhibitor of sheep scrapie PrPSc amplification (Figure 2A), but induced a low-level, dose-dependent amplification of BSE PrPSc (Figure 2B).

**Detection limit of BSE PrPSc using DSP-PMCA techniques**

The optimal concentration of DSP was estimated to be in the range of 0.05–0.75% (Figure 3); therefore, we used 0.5% DSP for subsequent experiments. We determined the detection limit of the DSP-PMCA technique and confirmed that PrPSc present in a 10⁻⁶ dilution of infected brain homogenate could be detected after one round of amplification, and both 10⁻⁸ and 10⁻⁹ dilutions tested positive for PrPSc after two rounds of amplification (Figure 4A). A PrPSc signal was detected in one of the 10⁻¹⁰ dilution samples, but no signal was detected in the more extreme dilution range, even after four rounds of amplification. Thus, the PrPSc detection sensitivity was improved 10⁸ times compared to no amplification. The 50% lethal dose (LD50) per gram of brain homogenate used as seed was determined in a previous study [22] by a bioassay using Tg(BoPrP)4092HOZ/Prnp0/0 (TgBoPrP) transgenic mice [23]. The infectious titer was 10⁶.7 LD50/g, and infectivity was confirmed in mice intracerebrally inoculated with up to a 10⁻⁶ dilution of the 10% brain homogenate. Therefore, our improved method was 10⁵ times more sensitive than the bioassay. The generation of spontaneous PrPSc, as has been reported for amplification in the presence of polyanions [24,25], was not observed with four rounds of amplification (Figure 4B).

**Infectivity of the PMCA product**

The PMCA product obtained after six rounds of amplification was diluted 10-fold and inoculated intracerebrally into TgBoPrP transgenic mice that overexpress bovine PrPC. Mice inoculated with the PMCA sample died after a mean of 243 days (Table 1). Control mice administered DSP (0.05%) or PrPSc (3.2×10⁻¹² dilution) at concentrations corresponding to the BSE seed dilution in the PMCA sample survived more than 500 days. The results of immunohistochemical analysis of the habenular nuclei and the midbrains from control and treated mice are shown in Figure 5. Vacuolation and PrPSc accumulation, which was occasionally observed as plaque-like PrPSc aggregates, were found in mice inoculated with the PMCA sample or the BSE-affected cattle brain.

---

**Figure 2. The effect of DSP and PPS on the amplification of scrapie and BSE PrPSc.** A. The PrPSc seed (10% brain homogenate from scrapie-infected sheep) was diluted to 10⁻⁴, and amplification was performed in the presence or absence (“No additive”) of sulfated compounds (potassium dextran sulfate: DSP and pentosan polysulfate: PPS). “No seed” designates the control in which PrPC substrate (10% homogenate of normal mouse brain) was amplified without sulfated compounds. B. Negative symbols indicate the results obtained for the control samples without BSE PrPSc seed, while positive symbols indicate the results obtained for the samples containing BSE PrPSc seed diluted to 10⁻⁴. Amplification was performed in the presence of PPS at the concentrations indicated.

doi:10.1371/journal.pone.0013152.g002

**Figure 3. Optimal DSP concentration for BSE PrPSc amplification.** The PrPSc seed was diluted to 10⁻⁴, and amplification was performed in the presence of the potassium dextran sulfate (DSP). “N” designates the control in which only PrPC substrate was amplified.

doi:10.1371/journal.pone.0013152.g003
homogenate, indicating that the amplified PrPSc was infectious and caused lesions typical of prion diseases.

**PrPSc** distribution in the tissues of BSE-affected cattle

Using our improved method, the distribution of PrPSc was examined in cattle that were orally administered a brain homogenate prepared from BSE-infected cattle. In the terminal disease stage in BSE-affected cow 5550, PrPSc was detected by conventional WB in several peripheral nervous tissues and the adrenal glands (Table 2). Moreover, PrPSc was detected by serial DSP-PMCA in the palatine tonsils, lymph nodes, ileocecal region, and muscular tissues (Figure 6A), whereas no PrPSc signal was detected in the corresponding tissue samples from uninfected control cow 2914 (Table 2 and Figure 6B).

We could not detect PrPSc in the spleen, blood, or cerebrospinal fluid (CSF) from BSE-affected cow 5550 in the end stage of disease, even after four rounds of amplification. Although an additional five tissue pieces were cut from both the central portion of the spleen and the splenic hilum for amplification, splenic PrPSc was not detected in any of these 10 tissue samples (Figure 7A). The distribution of PrPSc in the spleen was examined further in two more terminal disease-stage BSE-affected cattle, numbers 5499 and 5550.

### Table 1. Mean incubation time of TgBoPrP mice following intracerebral inoculation.

| Inocula                          | Transmission rate (total death/total number) | Mean incubation time ± SD (days) |
|----------------------------------|---------------------------------------------|----------------------------------|
| DSP dilution control (0.05%)     | 0% (0/3)                                    | >532                             |
| BSE PrPSc dilution control (3.2 × 10⁻¹⁴) | 0% (0/9)                                    | >532                             |
| R6 PMCA product                  | 100% (9/9)                                  | 243 ± 8                          |

Figure 4. BSE-PrPSc detection sensitivity. **A.** The PrPSc seed was diluted to 10⁻⁴ to 10⁻¹¹ with PrPC substrate, and samples were serially amplified in the presence of 0.5% potassium dextran sulfate (DSP). The duplicate amplified samples were analyzed after each round of amplification (R1–R4) by WB after PK digestion. **B.** No spontaneous generation of PrPSc was observed. Samples labeled “1” to “8” contained only PrPC substrate and were amplified in the presence of 0.5% DSP.

doi:10.1371/journal.pone.0013152.g004
**Figure 5. Immunohistological analysis of mice that succumbed to disease following intracerebral inoculation with PMCA product.** Results from mice inoculated with a 10% brain homogenate from BSE-infected cattle are shown for comparison. No vacuolation or PrP $^\text{Sc}$ accumulation was observed in the control mice inoculated with 0.05% DSP.

doi:10.1371/journal.pone.0013152.g005

**Table 2. Detection of PrP $^\text{Sc}$ by conventional WB analysis.**

| Cow Number | 2914 660 | 5499 | 5468 | 5550 | 9007 |
|------------|----------|------|------|------|------|
| Months post administration | Control (p.o.) | 34 | 42 (p.o.) | 57 (p.o.) | 17 (i.c.) |
| Clinical status at dissection | Normal | Affected | Affected | Affected | Asymptomatic |

| Tissue Type | 2914 660 | 5499 | 5468 | 5550 | 9007 |
|-------------|----------|------|------|------|------|
| Medulla oblongata | – | + | + | + | + |
| Spinal cord (cervical) | – | + | + | + | + |
| Spinal cord (thoracic) | – | + | + | + | + |
| Spinal cord (lumbar) | – | + | + | + | + |
| Palatine tonsil | – | – | – | – | ND |
| Spleen | – | – | – | – | ND |
| Mesenteric lymph node | – | – | – | – | ND |
| Rouviere lymph node | – | – | – | – | ND |
| Vagus nerve (cervical) | – | – | + | + | ND |
| Sympathetic nerve (thoracic) | – | – | – | – | ND |
| Stellate ganglion | – | + | + | + | ND |
| Radial nerve | – | – | – | – | ND |
| Ischiatic nerve | – | – | – | – | ND |
| Adrenal gland | – | – | + | + | ND |
| Lingual radix | – | – | – | – | ND |
| Triceps brachii muscle | – | – | – | – | ND |
| Semitendinosus muscle | – | – | – | – | ND |
| Ileocecal region | – | – | – | – | ND |
| White blood cells | – | – | – | – | ND |
| Plasma | – | – | – | – | ND |
| Cerebrospinal fluid | – | – | – | – | – |

p.o.: peroral inoculation; i.c.: intracerebral inoculation. Negative symbols indicate that no PrP $^\text{Sc}$ signal was detected in the samples before amplification. Positive symbols indicate that typical PrP $^\text{Sc}$ signals were detected in the samples. ND: not determined.

doi:10.1371/journal.pone.0013152.t002
and 5468. As was the case with cow 5550, splenic PrPSc was not detected in any of the 10 tissue samples from cow 5499 (Figure 7B). However, a PrPSc signal was detected in 3 of 10 tissue pieces from the spleen of cow 5468 (Figure 7C).

**PrPSc** distribution in the bodily fluids of BSE-affected cattle

Before amplification, PrPSc accumulation was confirmed using conventional WB analysis in the peripheral nervous tissues of cows 5499 and 5468 and in the adrenal gland of cow 5468 (Table 2). Individual differences in the distribution of PrPSc in CSF samples were observed in terminal-stage animals. PrPSc signals were detected in duplicate samples from cow 5468 after three rounds of amplification (Figure 7C) but were not detected in samples from cow 5499 (Figure 7B), as confirmed in samples from cow 5550 (Figure 6A).

We also examined the distribution of PrPSc in the salivary glands and saliva obtained from BSE-affected cattle. PrPSc was detected in the submandibular and parotid glands of cows 5468 and 5499 after two rounds of amplification (Figure 8A). In cow 5550, PrPSc was detected in the submandibular and sublingual glands (Figure 8B). Moreover, a PrPSc signal was detected in two of the quadruplicate saliva samples from cow 5550 after four rounds of amplification. The presence or absence of salivary PrPSc was investigated in intracerebrally infected cow 9007. PrPSc accumulation in the brain stem was found by conventional WB analysis 17 months after inoculation (Table 2), but the animal remained asymptomatic until sacrifice. PrPSc was detected in the sublingual and parotid glands after two rounds of amplification. In cow 9007, one of the duplicate saliva samples was found to be positive for PrPSc after four rounds of amplification (Figure 8C).
The present study is the first report describing ultrasensitive detection of BSE PrPSc in cattle. The determination that sulfated dextran compounds enhance the efficiency of *in vitro* BSE PrPSc amplification was unexpected because sulfated dextran has long been known as an antiscrapie agent both *in vivo* [26] and *in vitro* [27]. *In vitro* studies using recombinant PrP [28] and PrPSc purified from brain homogenate [29] have suggested that various polyanionic compounds increase the amplification of protease-resistant PrP. Therefore, endogenous polyanionic molecules such as sulfated glycans [28,29] and RNA [29] could be cofactors required to facilitate the propagation of PrPSc. Small and negatively charged dextran compounds (DSP and DSS-L) were most effective for *in vitro* amplification of bovine PrPSc in this study. These dextran compounds may accelerate the rate of PrPSc formation by acting as accessory molecules that facilitate or stabilize interactions between PrPSc, PrPC, and cofactors contained in brain homogenates. Since species-specific differences in cofactor preference for *in vitro* amplification of PrPSc have been reported [30], dextran compounds may interfere with PrPSc formation by acting as competitive inhibitors of the cofactors required for propagation of scrapie PrPSc.

The theory that PrPSc is widely distributed in various peripheral tissues in the terminal disease stage is strongly supported by our

Figure 7. PrPSc in spleen and bodily fluid samples obtained in the terminal disease stage. A total of 10 tissue pieces (0.2 g each) were cut from the central portion of the spleen (a–e) and splenic hilum (f–j) for amplification. Duplicate samples of spleen tissue from BSE-affected cows 5550 (A), 5499 (B), and 5468 (C) were examined. Blood and CSF samples from cows 5499 (B) and 5468 (C) were also examined. Horizontal lines indicate the positions of molecular weight markers corresponding to 37 kDa, 25 kDa, 20 kDa, and 15 kDa. WBC: White blood cells, CSF: Cerebrospinal fluid, Ns: No seed control.

doi:10.1371/journal.pone.0013152.g007

Figure 8. Detection of PrPSc by serial DSP-PMCA in saliva and salivary glands. Salivary PrPSc was evaluated in samples from an uninfected control cow (5660) and samples obtained from BSE-inoculated cows (5468, 5499, and 5550) in the terminal disease stage. Salivary PrPSc was also evaluated in an asymptomatic cow (9007) that had been intracerebrally inoculated with BSE. Horizontal lines indicate the positions of molecular weight markers corresponding to 37 kDa, 25 kDa, 20 kDa, and 15 kDa. Ns: No seed control.

doi:10.1371/journal.pone.0013152.g008
experimental results as well as previous findings, which demon-
strated a low level of infectivity in the tonsils [31] and muscles [32] of cattle that were orally administered a brain homogenate prepared from BSE-infected cattle. With regard to the level of PrPSc detected in muscle tissue, the level estimated from the amplification factor in PMCA was lower than that found in a brain homogenate diluted to $10^{-6}$ because no PrPSc signal was detected in the first round of amplification. In the mesenteric and Rouviere lymph nodes as well as the ileoceleal region, only one or two of the quadruplicate samples tested positive, even after four rounds of amplification. Given that PrPSc tends to aggregate, partial detection of PrPSc in the reaction may be due to the near absence of PrPSc; PrPSc levels in these tissues would have been equivalent to the levels found in brain homogenate dilutions of $10^{-10}$ to $10^{-11}$.

Although significant prionemia [33] and PrPSc distribution in the blood [34] have been demonstrated in scrapie-infected animals, the presence of PrPSc in the blood was not substantiated in the BSE-affected cattle used in our study, despite a dramatic improvement in the sensitivity of PrPSc detection. This observation was in agreement with the previous result showing that the disease is not transmitted through the blood of BSE-affected cattle [32,35]. Together with the scattered accumulation of PrPSc in the spleen and the low-level accumulation of PrPSc in the lymph nodes, the absence of detectable PrPSc in the blood of BSE-affected cattle suggests a neuronal rather than lymphoreticular progression of BSE PrPSc to the brain.

With regard to other bodily fluids, a bioassay of saliva from CWD-infected deer showed significant levels of infectious prions [36]. The presence of PrPSc in the salivary glands [37] and the amplification of PrPSc in concentrated buccal swab samples [38] have been reported in scrapie-infected sheep. Ours is the first report describing PrPSc detection in both the salivary glands and saliva of BSE-infected cattle. The salivary glands are regulated by parasympathetic nerves arising from the salivary nuclei of the medulla oblongata and sympathetic nerves arising from the thoracic portion of the spinal cord. Thus, it is possible that PrPSc is accumulated in the central nervous system and spread to the salivary glands through the autonomic nervous system, and that very small amounts of PrPSc were secreted into the saliva in BSE-infected cattle.

Our study demonstrated that the distribution of PrPSc was not restricted to the nervous system, and that PrPSc was able to spread to most of the peripheral tissues examined in the terminal disease stage. The finding that PrPSc could be amplified in saliva taken from an asymptomatic animal suggests a potential usefulness of this technique for BSE diagnosis. Detailed examinations of the temporal course of BSE infection and the incidence of PrPSc appearance in saliva, as well as studies of how infection route affects salivary PrPSc accumulation, will be necessary to confirm whether salivary PrPSc can serve as a reliable marker for BSE infection. The highly sensitive method we describe has other practical applications as well, such as evaluating the safety of livestock products and raw feed materials, and safety assurance of pharmaceutical and cosmetic products manufactured from bovine source materials.

Materials and Methods

Ethics Statement

All animal experiments were approved by the Animal Care and Use Committee (approval IDs: 450 and 08-009) and Animal Ethics Committee (approval IDs: 04-III-7 and 08-IV-32) of the National Institute of Animal Health.

Cattle

The cattle used in this study were imported from Australia. A c-BSE-infected brain homogenate (30 ml of a 10% homogenate) was orally administered to cattle (cows 5499, 5468, and 5550) ranging from 10 to 12 months in age. After 34 to 57 months, the animals were sacrificed and dissected in the terminal disease stage. Cow 9007 was intracerebrally inoculated with c-BSE-infected brain homogenate (1 ml of a 10% homogenate), sacrificed and dissected 17 months following inoculation, and the tissues were used for the analysis of salivary PrPSc. Normal 3- to 4-month-old cattle (cows 2914 and 5660) were used as controls.

Sample preparation

Tissues, white blood cells (WBCs), plasma, serum, CSF, and saliva were collected upon dissection and stored in small aliquots at $-80^\circ$C. Oral cavity saliva was collected by aspiration. Samples from each tissue (0.2 g) and WBCs (approximately $2 \times 10^6$ cells) were homogenized and suspended at 20% (w/v) in phosphate-buffered saline (PBS) containing $2 \times$ complete protease inhibitors (Roche Diagnostics).

PrPSc substrate

To avoid contamination, bovine PrPSc homogenates were prepared in a laboratory that had never contained infected materials. The brains of bovine PrPSc-overexpressing TgBoPrP transgenic mice and PrP knockout (PrP0/0) mice were homogenized separately in 20% (w/v) PBS containing $2 \times$ complete protease inhibitors. The homogenates were mixed with an equal volume of elution buffer (PBS containing 2% Triton X-100 and 8 mM EDTA) and incubated at 4°C for 1 h with continuous agitation. After centrifugation at 4500 g for 5 min, the supernatants were mixed in a 5:1 proportion of PrP0/0:TgBoPrP. This mixture was used as the PrPSc substrate. Dextran (Nacalai), dextran compounds (sodium dextran sulfate (DSS), potassium dextran sulfate (DSP), Nacalai; DEAE-dextran, Sigma), pentosan polysulfate (PPS, Elmiron, Janssen-Ortho), sulfated polysaccharide (sodium dextran sulfate (DSS), potassium dextran sulfate (DSP), Nacalai; DEAE-dextran, Sigma), pentosan polysulfate (PPS, Elmiron, Janssen-Ortho), sulfated polysaccharide (α-carrageenan, β-Caig, Nacalai), glycosaminoglycans (sodium chondroitin sulfate C (CSS), sodium heparan sulfate (HSS), Nacalai), and heparan sulfate proteoglycan (HSPG, Sigma) were dissolved in PBS or distilled water and added to the PrPSc substrate at the concentration indicated in the figures. For the amplification of sheep scrapie PrPSc, normal ICR mouse brains were homogenized in 10% (w/v) PBS containing complete protease inhibitors, 1% Triton X-100, and 4 mM EDTA. After centrifugation at 4500 g for 5 min, the supernatant was used as the PrPSc substrate.

PMCA

To examine the bovine PrPSc detection sensitivity, 100 μl of PrPSc substrate containing 0.5% DSP was mixed with 1/100 volume of 10% brain homogenate from cattle infected with c-BSE (infectivity titer = $10^{5.7}$ LD50/g) [20], and serial 10-fold dilutions were prepared of the PrPSc substrate containing 0.5% DSP. Homogenates of each tissue and WBCs, plasma, serum, CSF, and saliva were diluted 1:20 with the PrPSc substrate containing 0.5% DSP (total volume 100 μl) in an electron beam-irradiated polystyrene tube. Amplification was performed with a fully automatic cross-ultrasonic protein-activating apparatus (Elestein 070-CPR, Elekon Science Corporation) using 40 cycles of sonication in which a 3-s pulse oscillation was repeated five times at 1-s intervals, followed by incubation at 37°C for 1 h with agitation. For the amplification of PrPSc in various tissues from BSE-infected and control cattle (Figure 6), the PrPSc substrate containing 0.5% DSP was mixed with 1/20 volume of...
homogenized samples or bodily fluids (total volume 80 μl) in an
electron beam-irradiated 8-strip polystyrene tube specially
designated for PrPC propagation. PMCA was performed using 40
cycles of sonication (a pulse oscillation for 5 s, repeated five times
at 1-s intervals), followed by incubation at 37 °C for 1 h with
agitation. The 1:5 dilution of the PMCA product and subsequent
amplification was repeated three times.

Western blotting

Samples [10 μg/ml] were mixed with 10 μl of proteinase K (PK)
solution (100 μg/ml) after each round of amplification and
incubated at 37 °C for 1 h. The digested materials were mixed
with 20 μl of 2x SDS sample buffer and incubated at 100 °C for 5
minutes. The samples were separated by SDS-PAGE and
transferred onto a polyvinylidene fluoride membrane (Millipore).
After blocking, the membrane was incubated for 1 h with a
horseradish peroxidase (HRP)-conjugated T2 monoclonal anti-
body [39] diluted 1:10,000. After washing, the blotted membrane
was developed using the Immobilon Western Chemiluminescent
HRP Substrate (Millipore) according to the manufacturer’s
instructions. Chemiluminescence signals were analyzed with a
Light Capture system (Atto).

Bioassay

A 10% brain homogenate from c-BSE-infected cows was diluted
to 10−8 with PrPC substrate containing 0.5% DSP and amplified.
The PMCA product was diluted 1:5 with the PrPC source
containing 0.5% DSP, and a second round of amplification was
performed. The 1:5 dilution of the PMCA product and its
subsequent amplification were repeated five times. The product
from the sixth round was diluted 1:10 with PBS and inoculated
intracerebrally into TgBoPrP mice (20 μl per mouse). The PrPC
substrate containing 0.05% DSP and the PrPC substrate
containing the PrPC seed diluted to 3.2×10−12 were inoculated
as dilution controls for DSP and the PrPC seed, respectively.

Immunohistochemical analysis

The left hemisphere of the brain was fixed in 10% buffered
formalin for neuropathological analysis. Coronal brain sections
were immersed in 98% formic acid to reduce infectivity and
embedded in paraffin wax. Sections of 4-μm thickness were cut
and stained with hematoxylin and eosin (HE). Immunoreactive
PrPC was detected in brain sections using anti-PrP monoclonal
antibody F99/97.6.1 (VMRD) or 12F10 (SPI-bio) as the primary
antibody. An anti-mouse universal immunoperoxidase polymer
(Histofine simple stain MAX-PO (M), Nichirei) was used as the
secondary antibody, and 3,3′-diaminobenzidine tetrachloride
served as the chromogen.

Acknowledgments

We wish to thank the staff of the Prion Disease Research Center of
the National Institute of Animal Health for their assistance.

Author Contributions

Conceived and designed the experiments: YM. Performed the experiments:
YM, KY, HO, YMI, YM, TY. Wrote the paper: YM. Administered the
intracerebral inoculation of BSE: SO. Administered the oral
inoculation of BSE: TY. Supervised the study: SM.

References

1. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136–144.
2. Prusiner SB (1998) Prions. Proc Natl Acad Sci U S A 95: 13363–13363.
3. Wells GA, Scott AC, Johnson CT, Gunning RF, Hancock RD, et al. (1987) A novel progressive spongiform encephalopathy in cattle. Vet Rec 121: 419–420.
4. Wilesmith JW, Wells GA, Creamwell MP, Ryan JB (1988) Bovine spongiform encephalopathy: epidemiological studies. Vet Rec 122: 630–644.
5. Wilesmith JW, Ryan JB, Atkinson MJ (1991) Bovine spongiform encephalopathy: epidemiological studies on the origin. Vet Rec 128: 199–203.
6. Collinge J, Siddle KC, Mead J, Ironside J. Hill AF (1996) Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383: 615–690.
7. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
8. Collinge J, Desbruslais M, Joiner S, Sidle KC, Gowland I, et al. (1997) The same prion strain causes vCJD and BSE. Nature 389: 448–450.
9. Wilesmith JW, Ryan JB, Cranwell MP, Atkinson MJ (1991) Bovine spongiform encephalopathy: epidemiological studies. Vet Rec 123: 638–644.
10. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
11. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
12. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
13. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
14. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
15. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
16. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
17. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
18. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
19. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
20. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
21. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
22. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
23. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
24. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
25. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
26. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
27. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
28. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
29. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
30. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
31. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.
and observations on the distribution of lingual tonsil in slaughtered cattle. Vet Rec 156: 401–407.

32. Buschmann A, Groschup MH (2005) Highly bovine spongiform encephalopathy-sensitive transgenic mice confirm the essential restriction of infectivity to the nervous system in clinically diseased cattle. J Infect Dis 192: 934–942.

33. Houston F, McCutcheon S, Goldmann W, Chong A, Foster J, et al. (2008) Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 112: 4739–4745.

34. Castilla J, Sá P, Soto C (2005) Detection of prions in blood. Nat Med 11: 982–985.

35. Wells GAH, Dawson M, Hawkins SAC, Austin AR, Green RB, et al. (1996) Preliminary observations on the pathogenesis of experimental bovine spongiform encephalopathy. In: Gibbs CJJ, ed. Sixth International Workshop on bovine spongiform encephalopathy: the BSE dilemma. New York: Springer-Verlag. pp 28–44.

36. Mathiason CK, Powers JG, Dahmes SJ, Osborn DA, Miller KV, et al. (2006) Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 314: 133–136.

37. Vascellari M, Nonno R, Mutinelli F, Bigolaro M, Di Bari MA, et al. (2007) PrPSc in salivary glands of scrapie-affected sheep. J Virol 81: 4872–4876.

38. Maddison BC, Rees HC, Baker CA, Taema M, Bellworthy SJ, et al. (2010) Prions are secreted into the oral cavity in sheep with preclinical scrapie. J Infect Dis 201: 1672–1676.

39. Shimizu Y, Kaku-Ushiki Y, Iwamaru Y, Muramoto T, Kitamoto T, et al. (2010) A novel anti-prion protein monoclonal antibody and its single-chain fragment variable derivative with ability to inhibit abnormal prion protein accumulation in cultured cells. Microbiol Immunol 54: 112–121.